How do you determine which HER-2 positive patients should receive neoadjuvant chemotherapy?

Chemotherapy in combination with anti-HER2 antibodies should be recommended to a patient with node positive, HER2 positive breast cancer. Since NSABP B18 and B27 showed no difference in long term outcomes between patients treated with neo-adjuvant vs. adjuvant chemotherapy, you can go either way. I ...